跳至主要内容
MedPath Trial Home
临床试验
产品
机构
资讯
AI 研究
价格
Search
EN
登录
我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的
隐私政策
。
拒绝
接受
依乐韦 - NMPA Drug Approval Details
Approvals
/
NMPA
/
Zanamivir Powder for Inhalation
Approved
化学药品
Zanamivir Powder for Inhalation
LABORATOIRE GLAXOSMITHKLINE
🇨🇳 National Medical Products Administration
Approval Date
Apr 20, 2022
Approval ID
8H1Or8shs6m
Company
LABORATOIRE GLAXOSMITHKLINE
Type
化学药品
Approval Details
Approval Id
8H1Or8shs6m
Approval Number
国药准字HJ20140462
Generic Name
扎那米韦吸入粉雾剂
Generic Name En
Zanamivir Powder for Inhalation
Trade Name
依乐韦
Drug Type
化学药品
Dosage Form
吸入粉雾剂
Strength
5mg(以C₁₂H₂₀N₄O₇计)
Reg Date
2022-04-20
Expired Date
2027-04-19
Company Name
LABORATOIRE GLAXOSMITHKLINE
Production Company Name
GLAXO WELLCOME PRODUCTION
Company Detail Path
/organization/laboratoire-glaxosmithkline
Production Company Detail Path
/organization/glaxo-wellcome-production
Approved
Quick Info
Agency
NMPA
Country
🇨🇳
Approval Date
Apr 20, 2022
Approval ID
8H1Or8shs6m
Type
化学药品
Back to NMPA Approvals